# Rapport Therapeutics, Inc.: filings RAPP · Nasdaq · CIK 2012593 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rapp.md) · [Financials](/companies/rapp/financials.md) · [Filings](/companies/rapp/filings.md) · [Insiders](/companies/rapp/insiders.md) ## Reports and events: 38 filings Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 99, 144 30, 8-K 23, 3 19, 10-Q 7, 424B5 7, CORRESP 7, SCHEDULE 13G/A 6, UPLOAD 5, FWP 4, SC 13G 4, EFFECT 3, S-8 3, 10-K 2, ARS 2, DEF 14A 2, DEFA14A 2, S-3 2, SC 13G/A 2, SCHEDULE 13G 2, SEC STAFF LETTER 2, 305B2 1, 424B4 1, 8-A12B 1, CERT 1, DRS 1, DRS/A 1, DRSLTR 1, S-1 1, S-1/A 1, S-3ASR 1, SC 13D 1, SCHEDULE 13D/A 1). | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 17:12 ET | [8-K](/filings/0001193125-26-441851.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-441851 | | 2026-10-20 | 06:05 ET | [8-K](/filings/0001193125-26-425647.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-425647 | | 2026-08-05 | 07:30 ET | [10-Q](/filings/0001193125-26-333862.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333862 | | 2026-08-05 | 07:17 ET | [8-K](/filings/0001193125-26-333853.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333853 | | 2026-06-10 | 16:12 ET | [8-K](/filings/0001193125-26-265841.md) | 5.07 Shareholder vote results | 0001193125-26-265841 | | 2026-05-07 | 07:30 ET | [10-Q](/filings/0001193125-26-210355.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210355 | | 2026-05-07 | 07:15 ET | [8-K](/filings/0001193125-26-210324.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210324 | | 2026-04-23 | 07:20 ET | [DEF 14A](/filings/0001193125-26-171828.md) | Proxy statement, period 2026-06-10 | 0001193125-26-171828 | | 2026-04-21 | 16:50 ET | [8-K](/filings/0001193125-26-167078.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-26-167078 | | 2026-03-10 | 07:25 ET | [10-K](/filings/0001193125-26-099360.md) | Annual report, period 2025-12-31 | 0001193125-26-099360 | | 2026-03-10 | 07:11 ET | [8-K](/filings/0001193125-26-099336.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-099336 | | 2026-01-07 | 08:35 ET | [8-K](/filings/0001193125-26-005499.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005499 | | 2026-01-07 | 07:30 ET | [8-K](/filings/0001193125-26-005446.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-005446 | | 2025-11-06 | 07:30 ET | [10-Q](/filings/0001193125-25-268096.md) | Quarterly report, period 2025-09-30 | 0001193125-25-268096 | | 2025-11-06 | 07:15 ET | [8-K](/filings/0001193125-25-268072.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268072 | | 2025-09-18 | 17:32 ET | [SCHEDULE 13D/A](/filings/0001104659-25-091350.md) | Ownership report, active investor, amended | 0001104659-25-091350 | | 2025-09-10 | 17:22 ET | [8-K](/filings/0001193125-25-200205.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-200205 | | 2025-09-08 | 16:02 ET | [8-K](/filings/0001193125-25-198322.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-198322 | | 2025-09-08 | 06:12 ET | [8-K](/filings/0001193125-25-197610.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-197610 | | 2025-08-07 | 07:30 ET | [10-Q](/filings/0000950170-25-104565.md) | Quarterly report, period 2025-06-30 | 0000950170-25-104565 | | 2025-08-07 | 07:15 ET | [8-K](/filings/0000950170-25-104557.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-104557 | | 2025-06-18 | 16:30 ET | [8-K](/filings/0000950170-25-087921.md) | 5.07 Shareholder vote results | 0000950170-25-087921 | | 2025-06-02 | 16:07 ET | [8-K](/filings/0000950170-25-080247.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-080247 | | 2025-05-08 | 07:30 ET | [10-Q](/filings/0000950170-25-066393.md) | Quarterly report, period 2025-03-31 | 0000950170-25-066393 | | 2025-05-08 | 07:15 ET | [8-K](/filings/0000950170-25-066376.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066376 | | 2025-04-24 | 06:07 ET | [DEF 14A](/filings/0001193125-25-092133.md) | Proxy statement, period 2025-06-17 | 0001193125-25-092133 | | 2025-03-11 | 07:30 ET | [10-K](/filings/0000950170-25-036828.md) | Annual report, period 2024-12-31 | 0000950170-25-036828 | | 2025-03-11 | 07:15 ET | [8-K](/filings/0000950170-25-036822.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-036822 | | 2025-03-03 | 07:14 ET | [8-K](/filings/0001193125-25-043405.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-043405 | | 2025-01-10 | 06:30 ET | [8-K](/filings/0001193125-25-004045.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004045 | | 2024-11-07 | 07:30 ET | [10-Q](/filings/0000950170-24-122801.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122801 | | 2024-11-07 | 07:15 ET | [8-K](/filings/0000950170-24-122792.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122792 | | 2024-08-08 | 07:40 ET | [10-Q](/filings/0000950170-24-093334.md) | Quarterly report, period 2024-06-30 | 0000950170-24-093334 | | 2024-08-08 | 07:20 ET | [8-K](/filings/0000950170-24-093321.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093321 | | 2024-06-14 | 15:59 ET | [SC 13D](/filings/0001104659-24-071732.md) | Ownership report, active investor | 0001104659-24-071732 | | 2024-06-10 | 16:09 ET | [8-K](/filings/0001193125-24-158327.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-158327 | | 2024-06-03 | 06:08 ET | [S-1/A](/filings/0001193125-24-152294.md) | Registration statement, amended | 0001193125-24-152294 | | 2024-05-17 | 16:02 ET | [S-1](/filings/0001193125-24-141704.md) | Registration statement | 0001193125-24-141704 | Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 19:33 ET. No prices; not investment advice.